Results from a phase I/II trial of tinostamustine monotherapy in advanced solid tumours (NCT03345485): Safety and efficacy in a subset of patients (pts) with soft tissue sarcoma (STS)

被引：0
|
作者：
Chugh, R. [1 ]
Kummar, S. [2 ]
Schneider, R. E. [3 ]
Janik, T. [4 ]
Manamley, N. [5 ]
Hilgier, K. [4 ]
Strauss, J. [3 ]
机构：
[1] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI USA
[2] OHSU Knight Canc Inst, Div Hematol & Med Oncol, Ctr Hlth & Healing, Bldg 1 South Waterfront, Portland, OR USA
[3] Mary Crowley Canc Res Ctr, Med Oncol Dept, Dallas, TX USA
[4] Mundipharma Res Ltd, Clin Dev Oncol & Hematol, Cambridge, England
[5] Mundipharma Int, R&D, Cambridge, England
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1186
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1957P
引用
收藏
页码：S1048 / S1048
页数：1
相关论文
共 50 条
  • [1] RESULTS FROM A PHASE I/II TRIAL OF TINOSTAMUSTINE MONOTHERAPY IN ADVANCED SOLID TUMOURS (NCT03345485): SAFETY AND EFFICACY IN A SUBSET OF PATIENTS WITH ADVANCED OVARIAN CANCER (OVCA)
    Tinker, Anna V.
    Chugh, Rashmi
    Curigliano, Giuseppe
    Kummar, Shivaani
    Schneider, Reva
    Strauss, James
    Janik, Tomas
    Manamley, Nick
    Hilgier, Kasia
    Oaknin, Ana
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 : A252 - A252
  • [2] Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial
    Pacey, Simon
    Ratain, Mark J.
    Flaherty, Keith T.
    Kaye, Stanley B.
    Cupit, Lisa
    Rowinsky, Eric K.
    Xia, Chenghua
    O'Dwyer, Peter J.
    Judson, I. R.
    INVESTIGATIONAL NEW DRUGS, 2011, 29 (03) : 481 - 488
  • [3] Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial
    Simon Pacey
    Mark J. Ratain
    Keith T. Flaherty
    Stanley B. Kaye
    Lisa Cupit
    Eric K. Rowinsky
    Chenghua Xia
    Peter J. O’Dwyer
    I. R. Judson
    Investigational New Drugs, 2011, 29 : 481 - 488
  • [4] Phase II study of eribulin mesylate in patients (pts) with advanced soft tissue sarcoma (STS).
    Naito, Yoichi
    Kawai, Akira
    Araki, Nobuhito
    Ozaki, Toshifumi
    Sugiura, Hideshi
    Yazawa, Yasuo
    Morioka, Hideo
    Matsumine, Akihiko
    Hiraiwa, Masahide
    Asami, Shun
    Isu, Kazuo
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [5] Interim results of a phase II trial of first line retifanlimab (R) plus gemcitabine and docetaxel (GD) in patients (pts) with advanced soft tissue sarcoma (STS)
    Rosenbaum, Evan
    Qin, Li-Xuan
    Dickson, Mark Andrew
    Keohan, Mary Louise
    Gounder, Mrinal M.
    Chi, Ping
    Movva, Sujana
    Kelly, Ciara Marie
    Avutu, Viswatej
    Chan, Jason Earl
    Martindale, Moriah
    Adamson, Travis
    Clark, Camron
    Desir, Rhoena
    Biniakewitz, Matthew
    Cho, Grace
    Erinjeri, Joseph Patrick
    Lefkowitz, Robert A.
    Tap, William D.
    D'Angelo, Sandra P.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] A phase II study of oral ENMD-2076 administered to patients (pts) with advanced soft tissue sarcoma (STS).
    Loong, Herbert H. F.
    Blackstein, Martin E.
    Gupta, Abha A.
    Hogg, David
    Mackay, Helen
    Dhani, Neesha C.
    Oza, Amit M.
    Moore, Malcolm J.
    Razak, Albiruni R. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [7] Phase II study of oral ENMD-2076 administered to patients (pts) with advanced soft tissue sarcoma (STS).
    Loong, Herbert H. F.
    Blackstein, Martin E.
    Gupta, Abha A.
    Hogg, David
    Culala, Lindsay
    Nyquist-Schultz, Kjirsten
    Baker, Stephanie
    Wang, Lisa
    Razak, Albiruni R. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] Phase I/II study of docetaxel (D), gemcitabine (G), and bevacizumab (B) in patients (pts) with advanced or recurrent soft tissue sarcoma (STS)
    Verschraegen, C. F.
    Fekrazad, H. M.
    Rabinowitz, I.
    Quinn, R.
    Snyder, D.
    Judson, P.
    Purdy, M.
    Lee, F. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [9] Phase I/II study of docetaxel (D), gemcitabine (G), and bevacizumab (B) in patients (pts) with advanced or recurrent soft tissue sarcoma (STS)
    Verschraegen, C. F.
    Quinn, R.
    Rabinowitz, I.
    Arias-Pulido, H.
    Muller, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [10] Brivanib (BMS-582664) in advanced soft-tissue sarcoma (STS): Biomarker and subset results of a phase II randomized discontinuation trial.
    Schwartz, G. K.
    Maki, R. G.
    Ratain, M. J.
    Undevia, S. D.
    Jones, R. L.
    Rudin, C. M.
    Siu, L. L.
    Brockstein, B.
    Khayat, D.
    Gil, T.
    De Jonge, M. J.
    Sawyer, M. B.
    Evans, T. R. J.
    Medioni, J.
    O'Dwyer, P. J.
    Hartman, C.
    Poulart, V.
    Walters, I. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345